11,717 cases of Black Fungus in India so far, Gujarat has most cases: Govt

Gujarat and Maharashtra currently lead in Mucormycosis infections in the country with 2,859 and 2,770 cases respectively.

Black fungus
A doctor checks a patient for black fungus (Photo: PTI)
Press Trust of India New Delhi
2 min read Last Updated : May 26 2021 | 3:09 PM IST

The government has allocated 29,250 additional vials of Amphotericin-B drug to states and Union Territories, Union Minister for Chemicals and Fertilisers Sadananda Gowda said on Wednesday.

Amphotericin-B is used to treat Mucormycosis, also known as Black Fungus, which damages the nose, eyes, sinuses, and sometimes even the brain.

"Additional 29,250 vials of #Amphotericin- B drug, used in treatment of #Mucormycosis, have been allocated to all the States/UTs today. The allocation has been made based on the number of patients under treatment which is 11,717 across the country," Gowda tweeted.

The government has allocated 7,210 vials to Gujarat, followed by 6,980 vials to Maharashtra as part of the 29,250 fresh allocation.

Gujarat and Maharashtra currently lead in Mucormycosis infections in the country with 2,859 and 2,770 cases respectively.

Other states like Andhra Pradesh (1,930), Madhya Pradesh (1,910), Telangana (1,890), Uttar Pradesh (1,780), Rajasthan (1,250), Karnataka (1,220), Haryana (1,110) also received additional vials to counter the disease.

The government had allocated 19,420 vials of Amphotericin-B to various states, Union Territories (UTs) and Central Institutions on May 24. Earlier on May 21, the government had allocated 23,680 vials of the drug to various states and Union Territories.

Mucormycosis is a very rare infection which is caused by exposure to mucor mould which is commonly found in soil, plants, manure, and decaying fruits and vegetables. It affects the sinuses, the brain and the lungs and can be life-threatening in diabetic or severely immuno-compromised individuals such as cancer patients or people with HIV/AIDS.

The doctors in India are documenting an alarming number of cases of Mucormycosis among patients with COVID-19 and those who have recently recovered. They believe that Mucormycosis may be triggered by the use of steroids, a life-saving treatment for severe and critically ill COVID-19 patients.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :diseaseD V Sadananda Gowdadrugs

First Published: May 26 2021 | 2:33 PM IST

Next Story